Richard J. Auchus, MD, PhD: Adrenas: Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Aspect Biosystems: Consultant (); Crinetics: Consultant (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Lundbeck: Consultant (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Merck: Consultant (); Neurocrine: Consultant (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); OMass: Consultant (); Vertex: Consultant ()
Benjamin Wilson, BA: Neurocrine Biosciences: Consultant ()
Christa Flueck, MD: No financial relationships to disclose
In this interactive session, Dr. Richard Auchus will review emerging therapeutic strategies for adults with congenital adrenal hyperplasia, including novel ACTH‑targeted agents, optimized glucocorticoid regimens, and evolving approaches to managing androgen excess, fertility, and long‑term metabolic health. Participants will gain practical guidance on integrating new evidence into adult care pathways and navigating the transition from pediatric to adult management.
Learning Objectives:
Distinguish the complications observed in adults with congenital adrenal hyperplasia (CAH) due to the disease itself from those derived from long-term treatment with supraphysiological glucocorticoids (GCs).
List the sites of action for non-GC adjunct therapies for CAH that have been studied and are in trials.
Develop monitoring and GC-dose-reduction plans when adding adjunctive non-GC therapies in adults with CAH.
.jpg)
.jpg)
